Renaissance Technologies LLC Has $1.29 Million Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Renaissance Technologies LLC reduced its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 63.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 496,200 shares of the company’s stock after selling 879,600 shares during the period. Renaissance Technologies LLC owned approximately 0.55% of Aquestive Therapeutics worth $1,290,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Janney Montgomery Scott LLC acquired a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at about $1,456,000. Vanguard Group Inc. boosted its position in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after acquiring an additional 1,353,518 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $594,000. Lazard Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 115.5% in the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Aquestive Therapeutics in the first quarter valued at $54,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $4.95 on Friday. The business has a fifty day simple moving average of $4.36 and a two-hundred day simple moving average of $3.67. Aquestive Therapeutics, Inc. has a 1 year low of $1.25 and a 1 year high of $6.23. The company has a market capitalization of $450.64 million, a price-to-earnings ratio of -11.79 and a beta of 2.85.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the prior year, the business posted ($0.10) EPS. As a group, equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AQST shares. HC Wainwright boosted their price target on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Monday, September 30th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $12.00 price target (up previously from $10.00) on shares of Aquestive Therapeutics in a research report on Monday, September 30th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $8.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.